The stakes are enormous. Cancer affects roughly 20 million people each year, and projections suggest the annual burden could climb to 30.5 million by 2050. While tumor-intrinsic factors such as mutations and dysregulated signaling pathways remain central to oncology, researchers increasingly recognize that tumor-extrinsic factors, including everything non-cancerous within the tumor microenvironment and the broader tumor macroenvironment, powerfully influence disease trajectories. The cancer microbiome, spanning both the gut microbiome and the tumor-associated microbiome, has emerged as one of the most intriguing of these factors. Early studies focused on colorectal cancer simply because of anatomical proximity, but evidence now shows the gut microbiome acts systemically, modulating host immunity and metabolism across the body, and has been implicated in tumorigenesis, progression, treatment response, and immune-related adverse events.

The tumor-associated microbiome tells a different story. Unlike the gut’s rich microbial communities, intratumoral microbes exist in low abundance, sparse populations that vary dramatically by cancer type. Tumors exposed to the external environment, such as colorectal, gastric, and oral cancers, harbor relatively more microbial biomass, while pancreatic, liver, lung, and breast tumors are considered low-biomass settings. Evidence from experimental models and human datasets has linked these intratumoral communities to cancer progression, prognosis, and treatment response, and the microbes can localize both outside and inside cancer and immune cells, sometimes with distinct spatial organization. They influence their surroundings through infection, inflammation, and the production of metabolites, yet separating genuine microbial signals from laboratory contaminants remains one of the field’s hardest problems.

Computationally, the field has traveled a long road. Early studies relied on classical statistical tools such as differential abundance methods, including LEfSe and metagenomeSeq, to identify taxa associated with cancer risk, survival, and treatment response. But microbiome data are notoriously difficult: high-dimensional, sparse, zero-inflated, and compositional, properties that can reduce reproducibility. Network-based approaches like SparCC, CoNet, and SPIEC-EASI extended the toolkit by modeling microbial interactions and identifying community structures linked to cancer processes, yet they struggle with complex nonlinear relationships. Deep learning has now entered the picture, enabling integration of microbiome and multi-omics data to model higher-order interactions and improve biomarker discovery and clinical outcome prediction. The catch is that most AI models must work with high-dimensional but small-sample datasets, raising overfitting risks and threatening biomarker stability, especially without strong external or prospective validation.

Generating reliable data is the first battleground. Cancer microbiome studies produce diverse data types, each capturing different aspects of microbial composition, function, and host interaction. Partial 16S rRNA sequencing is affordable but usually resolves taxonomy only to the genus level; full-length 16S improves resolution to species; shotgun metagenomics captures all genes in a sample, enabling both taxonomy and functional prediction. Metatranscriptomics captures real-time gene expression but is technically demanding, limited by RNA instability and stringent handling requirements. Metaproteomics, which profiles expressed proteins, offers a more direct functional view but has barely touched cancer: a PubMed search as of June 2026 identified only nine cancer microbiome metaproteomics studies. Metabolomics rounds out the picture, measuring the small molecules microbes produce, with databases such as MiMeDB, the Natural Products Atlas, and MASST helping to attribute metabolites to microbial origins, while spatial metabolomics now maps region-specific metabolic changes within tumors.

Detecting intratumoral microbes demands special tools. Researchers have reanalyzed bulk RNA-seq and whole-genome sequencing data to infer microbial signals from non-human reads, but this approach is vulnerable to contamination, and a recent large-scale tumor whole-genome analysis found that after host subtraction and decontamination, detectable microbiome signals were largely restricted to orodigestive cancers. Specialized pipelines have emerged to help: CSI_Microbe extracts microbial reads from The Cancer Genome Atlas sequencing data, SAHMI denoises microbial signals from single-cell RNA sequencing, and INVADEseq adds a primer targeting the conserved 16S region to map microbes within individual human cells. Spatial technologies such as imaging mass cytometry with mass-tagged antibodies and desorption electrospray ionization mass spectrometry imaging can visualize microbial presence alongside host immune and tumor cells. The review also lays out practical standards for credible signals: negative controls, conservative host-read subtraction, evaluation of batch structure, and orthogonal validation through qPCR, culture, in situ hybridization, or spatial imaging.

Once data are trustworthy, AI modeling begins in earnest, and the review offers a sobering lesson: bigger is not always better. Benchmarking studies show that classical, regularized models remain strong baselines. In a 16S rRNA benchmark with 490 subjects and 6,920 features, L2-regularized logistic regression matched random forest performance while training faster and remaining more interpretable. A larger benchmark across 83 gut microbiome cohorts and 20 diseases found ridge regression and random forest among the best performers, with neural networks and gradient boosting not consistently outperforming them. Deep learning architectures, including multilayer perceptrons, transformers, graph neural networks, and autoencoders, expand modeling capacity for nonlinear and structure-aware analysis, and foundation models pretrained on large-scale microbiome data, such as MGM, GenomeOcean, and Evo2, promise transferable representations, but fine-tuning on small cancer cohorts still risks overfitting, and interpretability remains limited.

The applications are already impressive. Multi-view deep learning frameworks distinguish metastatic from non-metastatic colorectal cancer using gut microbial features, while methods like GDmicro combine graph convolutional networks with domain adaptation to improve cross-cohort robustness against differences in region, diet, and sequencing protocols. Integration frameworks such as VTrans use large-scale pretraining and selective co-attention to combine microbiome features with host transcriptomics and copy-number profiles, enhancing survival risk stratification in small cohorts. Interpretability methods, from SHAP values and integrated gradients to graph-based community explanations like Micah, are evolving from simple feature ranking toward direction-aware, network-level insights. Looking ahead, causal AI frameworks such as DAG-deepVASE, which combines deep networks with knockoff features to identify nonlinear causal relationships, could move the field beyond pure association, though the review stresses that such findings remain hypothesis-generating until validated.

Mechanistic evidence is accumulating for real biological effects. Intratumoral Fusobacterium nucleatum has been implicated in promoting tumor progression, metastasis, and chemoresistance through immune modulation, autophagy activation, and oncogenic signaling, while enterotoxigenic Bacteroides fragilis promoted tumorigenesis and metastasis in breast cancer models. Gut microbes directly metabolize therapeutic drugs: bacterial β-glucuronidase reactivates the inactive metabolite of irinotecan in the gut, causing diarrhea, and inhibiting this enzyme can preserve drug efficacy while limiting toxicity. In immunotherapy, antibiotic use before immune checkpoint inhibitor treatment is associated with poorer response and survival, fecal microbiota transplantation from responders enhances anti-PD-1 responses in preclinical models, and findings from the CIAO clinical trial showed that total intratumoral bacterial abundance was the only microbiome-related feature predicting immune checkpoint blockade response in head and neck cancer, with higher abundance linked to an immunosuppressive microenvironment.

Translating these discoveries into the clinic is the final and steepest climb. The review emphasizes a three-stage evidentiary hierarchy, analytical validation, clinical validation, and demonstrated clinical utility, that most cancer microbiome biomarkers have not yet climbed. Fecal metagenomic classifiers for colorectal cancer are the most mature, retaining accuracy around an AUC of 0.8 in independent cohorts, while tumor-intrinsic signatures have faced serious challenges over host-read misclassification and normalization artifacts. Interventional strategies show encouraging but preliminary signals, with responder-derived fecal transplants reinstating anti-PD-1 responses in some ICI-refractory melanoma patients, yet a fatal transmission of a drug-resistant bacterium during fecal transplantation underscores the safety stakes. The path forward, the authors argue, requires standardized reporting under frameworks like STORMS, contamination-aware pipelines, prospective multicenter validation, and AI systems treated as prioritization tools rather than oracles. Emerging paradigms, including agentic AI systems like Eubiota, human-in-the-loop frameworks, and digital twin approaches, may eventually knit microbiome data into iterative clinical translation, but only if every model is paired with uncertainty estimation and external validation. The era of the cancer microbiome is no longer a question of whether microbes matter in oncology, but of whether the field can prove it rigorously enough for patients to benefit.

Subject of Research: Integration of multi-omics technologies and artificial intelligence for decoding the cancer microbiome and translating discoveries into clinical oncology applications

Article Title: Decoding the cancer microbiome: multi-omics, AI, and translational opportunities

Article References: Decoding the cancer microbiome: multi-omics, AI, and translational opportunities. (n.d.). https://doi.org/10.1186/s13059-026-04284-8

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04284-8

Keywords: cancer microbiome, tumor-associated microbiome, gut microbiome, multi-omics, artificial intelligence, deep learning, biomarker discovery, immunotherapy response, Fusobacterium nucleatum, metagenomics, precision oncology, clinical translation

Colorectal cancer, one of the leading causes of cancer-related mortality worldwide, presents a complex biological challenge. Traditional understanding of CRC has emphasized genetic mutations and environmental factors; however, recent insights into the tumor microenvironment have shifted the focus toward lipid metabolism and its contributions to cancer progression. DPPC, a surfactant phospholipid predominantly found in biological membranes, has been observed in increasing concentrations within the tumor microenvironment of CRC patients. This study meticulously dissects the mechanisms by which DPPC influences both tumor cells and the surrounding immune landscape.

The researchers utilized a robust multi-omics framework that included genomics, transcriptomics, proteomics, and metabolomics, thus enabling a comprehensive analysis of the biochemical interplay within the tumor microenvironment. By integrating these diverse data types, the study offers a panoramic view of how elevated levels of DPPC are associated with altered metabolic signatures in CRC. The findings underscore the critical role of lipid metabolites in reshaping tumor biology and highlight the need to consider metabolic deregulation in cancer research and treatment.

Machine learning algorithms played a central role in discerning patterns from the vast datasets generated, allowing the researchers to predict CRC patient outcomes based on lipid profiles. These predictive models could revolutionize personalized medicine by enabling clinicians to tailor specific interventions to patients based on their unique metabolic landscapes. The team’s ability to correlate high DPPC levels with poorer prognoses sets a precedent for investigating other lipids as potential biomarkers for CRC.

In their analysis, the researchers observed that DPPC not only supports the proliferation of tumor cells but also modulates the immune response within the tumor microenvironment. This dual function raises intriguing questions about the potential of DPPC as a therapeutic target. By inhibiting DPPC synthesis or signaling pathways, there exists the possibility of disrupting the supportive niche that tumors rely upon for growth and immune evasion.

Moreover, the study highlights the complexity of lipid interactions within the tumor microenvironment. DPPC is not acting in isolation; rather, it is part of a broader lipidomic landscape that influences tumor behavior. Understanding the interplay between DPPC and other lipids may yield critical insights into the intricate mechanisms of CRC progression and facilitate the development of combination therapies that simultaneously target multiple pathways.

The implications of this research extend beyond colorectal cancer, as lipid metabolism plays a fundamental role in various cancers. By elucidating the mechanisms through which DPPC contributes to tumor dynamics, this study provides a valuable model for exploring lipid roles in other malignancies. The cross-disciplinary approach utilized in this research reflects the necessity of integrating molecular biology, medicinal chemistry, and computational biology for advancing cancer therapies.

Further inquiries are warranted to determine the exact pathways through which DPPC influences immune cell function and tumor behavior. The potential for targeting DPPC-related pathways presents an exciting opportunity for the development of novel therapeutic strategies. With the emergence of precision medicine, identifying lipid signatures associated with tumorigenesis could empower oncologists to devise more effective treatment plans tailored to individual metabolic profiles.

As the research community continues to unravel the complexities of cancer biology, studies like this serve as critical reminders of the importance of holistic approaches. The integration of multi-omics data offers a treasure trove of information that can elucidate the multifaceted nature of cancer. As researchers delve deeper into the metabolic intricacies of tumors, the potential for novel therapeutic interventions remains vast.

The study by Li and colleagues exemplifies the promise held by innovative research methodologies in uncovering underlying cancer mechanisms. By spotlighting DPPC’s role in colorectal cancer, this pivotal research contributes to a growing body of evidence that emphasizes the significance of metabolic factors in oncogenesis. As science continues to advance, the hope is that such findings will translate into tangible clinical benefits that improve patient outcomes.

In conclusion, the role of DPPC in colorectal cancer progression is becoming increasingly recognized, and this comprehensive study lays the groundwork for further investigations into lipid metabolism as a key player in cancer biology. The intersection of multi-omics approaches and machine learning presents a powerful lens through which we can view complex biological systems, underscoring the importance of continued exploration in this dynamic field.

The fight against colorectal cancer may be on the brink of a transformative breakthrough, with researchers now able to target metabolic pathways in conjunction with traditional therapeutic strategies. DPPC’s newfound prominence in this context may represent a turning point in how we understand and treat this prevalent malignancy. As we look to the future, the integration of lipidomics into routine cancer research could greatly enhance our ability to combat colorectal cancer and potentially other malignancies.

With ever-increasing insight into the tumor microenvironment and its myriad interactions, a more nuanced understanding of cancer will emerge. As we harness the power of multi-omics and machine learning, the horizon of cancer treatment expands, promising new strategies that not only target tumor cells but also the multifaceted biological systems within which they reside.

Subject of Research: The role of dipalmitoylphosphatidylcholine (DPPC) in colorectal cancer progression and tumor immune microenvironment remodeling.

Article Title: Multi-omics and machine learning reveal DPPC as a key contributor to colorectal cancer progression and tumor immune microenvironment remodeling.

Article References:

Li, X., Dong, H., Jin, Z. et al. Multi-omics and machine learning reveal DPPC as a key contributor to colorectal cancer progression and tumor immune microenvironment remodeling.
J Transl Med (2026). https://doi.org/10.1186/s12967-025-07576-y

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07576-y

Keywords: DIPALMITOYL PHOSPHATIDYLCHOLINE, COLORECTAL CANCER, IMMUNE MICROENVIRONMENT, MACHINE LEARNING, MULTI-OMICS, TUMOR PROGRESSION

Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, with prognosis often grim due to late detection and limited therapeutic options. Chronic inflammation is known to play a pivotal role in tumorigenesis and cancer progression, yet the precise molecular and microbial mechanisms bridging systemic inflammation and gastric cancer aggressiveness have eluded comprehensive elucidation. The recent study bridges this gap by dissecting how SIRI, an emerging inflammatory biomarker, influences the gut microbiome and metabolic profiles of affected patients.

The research cohort comprised 495 gastric cancer patients whose SIRI levels were quantified and stratified into high and low groups using a rigorous cutoff value of 2.6. This stratification allowed in-depth survival analysis, revealing that patients with high SIRI exhibited significantly diminished overall survival (OS) and disease-free survival (DFS). Notably, the hazard ratios indicated nearly double the risk of death and more than a threefold increased risk of disease recurrence for high SIRI individuals, underscoring the biomarker’s powerful prognostic value.

To unravel the biological underpinnings behind these stark clinical disparities, the investigators performed an integrative multi-omics analysis on stool specimens from a subset of 45 patients. This subset included 21 with high and 24 with low SIRI levels, enabling direct comparison of gut microbial communities and metabolomic signatures. Employing state-of-the-art sequencing and untargeted metabolomics methods, they mapped the microbial taxa and metabolic compounds characteristic of each inflammatory state.

Intriguingly, the microbiota landscape of high SIRI patients was marked by a disproportionate surge in the genus Escherichia-Shigella, notorious for its pro-inflammatory and pathogenic potential. Concomitantly, taxa such as Blautia and Klebsiella, often associated with gut homeostasis and beneficial metabolic functions, were significantly depleted. This microbial imbalance hints at an inflammatory milieu conducive to gastric cancer progression, shaped profoundly by gut dysbiosis.

Metabolomic profiling mirrored these alterations, revealing that high SIRI status correlated with elevated levels of N-Acetylcadaverine and Epsilon-caprolactam—metabolites implicated in nitrosative stress and cellular toxicity pathways that may exacerbate mucosal damage and tumorigenesis. Conversely, protective antioxidant-related metabolites like S-(PGA2)-glutathione were reduced, underscoring a compromised metabolic defense system intrinsic to high systemic inflammation contexts.

Beyond independent microbial or metabolic shifts, integrative correlation analyses elucidated significant microbe-metabolite linkages that highlight complex biochemical interactions. For instance, Escherichia-Shigella abundance correlated tightly with increased N-Acetylcadaverine and Epsilon-caprolactam concentrations, illuminating a potential causal axis where gut pathogens drive detrimental metabolite accumulation, thereby amplifying inflammatory and carcinogenic processes.

This multifaceted evidence situates SIRI as not just a prognostic index but as a surrogate marker reflecting profound perturbations in the gut ecosystem and host metabolism. The authors propose that these non-invasive microbial and metabolic signatures could revolutionize risk stratification in gastric cancer, enabling earlier intervention and tailored therapeutic regimens based on individualized inflammatory and microbiome profiles.

Importantly, this research underscores the systemic nature of gastric cancer, transcending traditional tumor-centered models to encompass holistic patient physiology, including immune responses and gut microbial co-factors. The interdependence of host inflammation, microbial dysbiosis, and metabolite milieu forms a vicious cycle potentially driving malignancy progression and resistance to conventional therapies.

Looking forward, the study invites further exploration into therapeutic strategies that modulate gut microbiota or metabolic pathways as adjuncts to standard oncological care. Approaches such as targeted probiotics, dietary intervention, or metabolite inhibition could attenuate the adverse inflammatory signatures associated with high SIRI, possibly improving patient survival and quality of life.

Moreover, the methodological framework—combining robust clinical data with advanced multi-omics analytics—sets a new paradigm for cancer biomarker discovery. This integrative approach promises to unveil latent biomarkers within complex biological systems, fostering personalized medicine strategies that harness patient-specific inflammatory and microbial profiles.

While this study has profound implications, the authors acknowledge the need for larger, longitudinal cohorts to validate these findings and assess how dynamic changes in SIRI, microbiota, and metabolism impact treatment response over time. Additionally, mechanistic studies are warranted to unravel the molecular pathways linking identified microbes and metabolites to gastric tumor biology.

In sum, the elucidation of gut microbiota and metabolomic disruptions tied to systemic inflammation in gastric cancer provides a critical leap toward comprehending and combating this formidable disease. This research not only spotlights SIRI’s prognostic prowess but also opens avenues for innovative, integrated diagnostic and therapeutic strategies rooted in the microbiome-metabolite-inflammation axis.

As mounting evidence cements the gut microbiome’s central role in cancer etiology and progression, this study exemplifies how multi-omics technologies can decode the intricate biological networks at play. The hope is that such discoveries will translate rapidly into clinical practice, heralding an era where gastric cancer prognosis and management are precisely attuned to the patient’s unique biological signature.

This multi-disciplinary endeavor reflects a broader trend in oncology research, moving toward embracing complexity and systemic interconnectivity rather than relying solely on genomic or histopathological data. It exemplifies how harnessing the synergy of microbial ecology, metabolic biochemistry, and immunology can yield transformative insights into cancer pathogenesis and patient care.

Ultimately, the study by Zou et al. catalyzes a paradigm shift, converting a straightforward inflammatory index into a window onto complex gut-environmental interactions that drive cancer progression. Its implications extend beyond gastric cancer, potentially informing biomarker discovery and therapeutic innovation across diverse malignancies where inflammation and microbiota interplay is critical.

This triumph of integrative science highlights the power of viewing disease through an interconnected biological lens and sets a compelling precedent for future research aiming to transform cancer prognosis through precision inflammation and microbiome monitoring.

Subject of Research:
Multi-omics analysis of gut microbiota and metabolism in relation to systemic inflammation in gastric cancer patients.

Article Title:
Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI.

Article References:
Zou, F., Deng, S., Liu, B. et al. Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI. BMC Cancer 25, 1433 (2025). https://doi.org/10.1186/s12885-025-14852-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14852-z